Medigene (ETR:MDG1) Second Quarter 2024 Results
Key Financial Results
- Revenue: €1.46m (down 6.0% from 2Q 2023).
- Net loss: €4.08m (flat on 2Q 2023).
- €0.15 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medigene Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 7.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.1%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.
Performance of the market in Germany.
The company's shares are up 6.8% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Medigene (at least 2 which make us uncomfortable), and understanding them should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:MDG1
Medigene
A biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
Medium-low with adequate balance sheet.
